Cardiac Amyloidosis and the V142I Transthyretin Variant

What is the natural history and cardiovascular burden of the V142I transthyretin variant among US Black individuals who carry this variant? Senthil Selvaraj, MD, MS, MA, from Duke University, and Scott D. Solomon, MD, from Brigham and Women’s Hospital, discuss this and more with JAMA Executive Editor Gregory Curfman, MD. Related Content:

• Cardiovascular Burden of the V142I Transthyretin Variant
• Addressing Health Disparities—The Case for Variant Transthyretin Cardiac Amyloidosis Grows Stronger
• Heart Failure in African American Individuals, Version 2.0
• Cardiac Amyloidosis Due to Transthyretin Protein